The effect of Helicobacter pylori eradication on insulin resistance and HbA1c level in people with normal glucose levels: a prospective study

Zeynal Dogan, Murat Sarikaya, Bilal Ergul, Levent Filik

Background and Aim. Helicobacter pylori (H. pylori) infection is reported to be associated with various extragastro-intestinal conditions such as insulin resistance, diabetes mellitus and metabolic syndrome. These conditions are attributed to systemic inflammation, leptin or ghrelin changes due to H. pylori infection. Therefore, increasing trends in the management of H. pylori infection are ordered to maintain glycemic control. In this study, we evaluated the effect of H. pylori eradication on insulin resistance in patients with normal blood glucose concentrations.

Method. A total of 370 patients with successful eradication were included in the study. Patients with H. pylori were given triple eradication treatment. All patients with H. pylori infection were tested for fasting glucose, fasting insulin, glicated hemoglobin (HbA1c) at baseline and 6 months after eradication treatment. Also, insulin resistance was calculated using the homeostatic model assessment of insulin resistance (HOMA-IR). Body mass index was also determined as a metabolic syndrome criteria effecting insulin resistance.

Results. There were significant differences in fasting glucose, fasting insulin, HbA1c, and HOMA-IR values between before treatment and after treatment (P <0.04, <0.01, <0.01, <0.01). The favorable effect of eradication was more significant in patients with BMI≥25 mg/m² (P<0.05).

Conclusion. Eradication treatment has beneficial effects on insulin resistance in patients with normal glucose concentrations.

Key words: Helicobacter pylori, insulin resistance, body mass index

INTRODUCTION

H. pylori is a noninvasive, microaerophile, and spiral-shaped microorganism that causes severe gastric pathologies such as chronic active gastritis, peptic ulcer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. H. Pylori is responsible for both gastric local inflammation and a systemic inflammation leading to extra-gastrointestinal tract conditions such as cardiovascular diseases, idiopathic thrombocytopenic purpurae (ITP), unexplained iron deficiency anemia, diabetes mellitus and insulin resistance. The Maastricht IV consensus report declares that H. pylori eradication does not cause or worsen obesity and related illnesses. Recent studies showed the relationship between H. pylori and insulin resistance or diabetes. Accordingly, a favorable effect of H. pylori eradication on insulin resistance was also documented in some studies. However, this relationship is not well defined yet due to some pitfalls in those studies. If well-defined association between H. pylori and insulin resistance is established, we obviously change our approach to insulin resistance, type 2 diabetes and also metabolic syndrome regarding H. pylori. On the other hand, H. pylori and HbA1c level association in people with normal blood glucose concentrations is another major issue of concern. In this regard, we aimed to investigate the effect of H. pylori eradication therapy on insulin resistance in patients with normal blood glucose concentrations.

PATIENTS AND METHODS

This study is a prospective, controlled, single-blind study carried out in our gastroenterology department. Consecutive patients with dyspepsia were recruited between July 2012 and August 2012. In total 463 patients with H. pylori received triple eradication therapy. All 370 patients (female: 202, male: 168) whose H. pylori was eradicated were included in the study. The mean age of the patients was 39.4±14.2 years. Ninety three patients (20%) whose H. pylori eradication was unsuccessfull were excluded from the study and have been followed up in our outpatient clinic to be treated with other eradication regiments.

Informed consent was obtained from all patients. After approval, esophagogastroduodenoscopy was performed. Two specimens from the incisura angularis, antrum and corpus were obtained for histological analysis during endoscopy. The rapid urease test (RUT), (Endochoice Inc. US. CLO-rapid urease test) for qualitative assessment of urease activity, was performed on all those biopsy specimens for detecting H.pylori infection. Fresh antral and corporal biopsies were placed on slides and the results
were considered negative if there was no color change from yellow in one hour, while samples with color change toward pink were considered positive. The RUT can detect the presence of *H. pylori* within one hour with a satisfactory accuracy (>90%) (ref. 13).

Patients with *H. pylori* infection were eradicated with triple treatment (amoxicillin 1000 mg, clarithromycin 500 mg, lansoprazole 30 mg, twice daily) for 14 days. Lansoprazole treatment (30 mg twice daily) was continued by all patients for 4 weeks more to complete the eradication therapy. The UBT using essentially [13C] urea remains the best test to diagnose *H. pylori* infection, has a high accuracy and is easy to perform. UBT’s sensitivity is 88-95% and specificity is 95%-100% (ref. 14).

All patients with *H. pylori* infection were tested for fasting glucose, fasting insulin, glycated hemoglobin (HbA1c) at baseline and 6 months after eradication treatment. Blood samples were obtained following an overnight (12 h) fast. HbA1c is routinely measured according to DCCT (Diabetes Control and Complications Trial) in our laboratory. This was why we also switched HbA1c values to IFCC (International Federation of Clinical Chemistry) via formulation of IFCHBA1c (mmol/mol) = [DCCTHBA1c(%) - 2.15] / 0.915 in that study (Table 2).

Also, insulin resistance was calculated using the homeostatic model assessment of insulin resistance (HOMA-IR= fasting glycaemia (mg/dL) X fasting insulinaemia (μU/mL)/405) which was first described by Matthews at al. in 1985 (ref. 15). Body mass index (BMI) was calculated as body mass (kg)/height (m²) for all patients at baseline and three months after eradication. No diet modification for weight loss was advised.

**Exclusion criteria**

Patients with hematologic abnormality, liver and kidney disease, diabetes mellitus and metabolic syndrome were excluded. Patients with a history of previous *H. pylori* eradication treatment, using NSAIDs, antibiotics, proton pump inhibitors within a month were also excluded from the study. Fasting glucose higher than 105 mg/dL, BMI > 30 kg/m², age younger than 16 years, pregnancy, lactation, alcohol consumption, and smoking were other exclusion criteria.

The patients who had *H. pylori* treatment failure (n=93, 20% of patients) were also excluded from the study.

This study was approved by the local ethics committee.

**Statistical analysis**

Numerical values were defined as means±standard deviation. Shapiro-Wilk test was used to determine the distribution of parameters. Paired-Samples t-Test was used for comparing the pre-treatment and post-treatment values of patients. *P* < 0.05 was considered statistically significant. Statistical analysis were performed by SPSS v. 16, SPSS Inc. (Chicago, Illinois, USA).

**RESULTS**

The demographic and laboratory findings are shown in Table 1. There was no significant differences for age, alanine aminotransferase (ALT) and creatinine (Cre) between males and females (*P* > 0.05). Hemoglobin level was lower and BMI was significantly higher in females compared to males (Table 1). There were significant differences in fasting glucose, fasting insulin, HbA1c, and HOMA-IR values between before treatment and after treatment (*P* < 0.05). No significant differences was found in baseline BMI compared to after treatment (Table 2).

**Table 1.** Demographic and laboratory characteristics of patients.

|                | Female (n=202) | Male (n=168) | *P*  
|----------------|---------------|--------------|----
| Age (year)     | 39.3±1.4      | 38.6±13.7    | >0.66
| Height (meter) | 1.59±0.4      | 1.71±0.5     | <0.001
| Body mass (kilogram) | 65.3±1.0     | 72.8±8.7     | <0.001
| BMI (kilogram/m²) | 25.8±4.1     | 24.9±3.2     | <0.027
| Hb (g/dL)      | 13.2±1.1      | 13.8±1.2     | <0.007
| ALT (IU/L)     | 21.4±2.8      | 19.9±5.9     | >0.569
| Cr (mg/dL)     | 0.86±0.13     | 0.88±0.15    | >0.419

BMI: Body mass index, Hb: Hemoglobin, ALT: Alanin aminotransferase, Cr: Creatinin

**Table 2.** Potential laboratory markers of HP activity at baseline (before HP eradication) and after 6 weeks of eradication therapy.

|                     | Before eradication (n=370) | After eradication (n=370) | *P*  
|---------------------|----------------------------|---------------------------|----
| Fasting glucose (mg/dL) | 93.36±7.41                | 92.18±7.26                | <0.04
| Fasting insulin (μU/mL) | 11.24±6.38                | 10.92±5.13                | <0.01
| HOMA-IR (fasting glucose, fasting insulin, HbA1c, and HOMA-IR values between before treatment and after treatment (*P* < 0.05). No significant differences was found in baseline BMI compared to after treatment (Table 2). | 2.61±1.55 | 2.58±1.61 | <0.01
| HbA1C (%)           | 5.50±0.35                 | 5.48±0.33                 | <0.01
| HbA1C (mmol/mol)    | 36.6±3.8                  | 36.4±3.6                  | <0.01
| BMI (kilogram/m²)   | 25.4±4.1                  | 25.5±4.1                  | >0.189

HOMA-IR: homeostatic model assessment-insulin resistance, HbA1C: Hemoglobin A1C (glycated hemoglobin), BMI: Body mass index
BMI: Body mass index

When we chose a BMI value of 25, the favorable effect of eradication was statistically significant (Table 3).

DISCUSSION

This study has several important outcomes. The first major result is favorable HbA1c changes obtained after H. pylori eradication. That result is especially important because the study group was selected from the persons with normal blood glucose concentrations. Based on these results we could suggest eradication of H. pylori to prevent diabetes and associated diseases. Herein, BMI of 25 is important when selecting the population for association of blood glucose concentrations and H. pylori. A BMI cut-off value is an important tool to answer the question “who will benefit H. pylori eradication”.

Indeed, the favorable effect of H. pylori eradication on insulin resistance was previously documented in some studies[18-20]. However, this relationship was not clear due to methodological pitfalls in those studies. Those pitfalls were selection of inappropriate or insufficient methods used for detecting of H. pylori infection and the population differences among different studies[16,17]. The relationship between inflammation and insulin resistance in type 2 diabetes has already been shown[21]. Similarly, a higher prevalence of H. pylori in patients with diabetes was shown in Turkey[22].

H. pylori causes systemic host inflammatory responses including cytokine production such as TNF-α, CRP, IL-1β, lipid-peroxides, hyperhomocysteinemia (HHcy) and intercellular-and vascular-cell adhesion molecules (ICAM-1 and VCAM-1, respectively) (ref.22-26). H. pylori infected gastric mucosa produces higher level of IL-17 which stimulates the synthesis of IL-8, an important neutrophil chemoattractant. IL-17 is also suggested to play a major role in the inflammatory response to the H. pylori infection. Those inflammatory cascades especially TNF-α and CRP are proposed be strongly associated with insulin resistance[27-29]. The systemic inflammation due to H. pylori might also lead to impairment in insulin secretion[30]. Pancreatitis, insulin producing pancreatic beta-cells injury, caused by systemic inflammation of H. pylori was also proposed to explain this association[31,32].

Leptin related mechanism is another proposed mechanism in this regard. In a study, leptin levels were found to be higher in patients with H. pylori infection. Authors suggested that high levels of leptin decrease the effect of insulin by phosphorylation of Ser-318 of IRS-1 (ref.33). Another study showed that low plasma ghrelin levels are associated with elevated fasting insulin levels and insulin resistance[34]. Plasma ghrelin concentrations were significantly lower in H. pylori positive than H. pylori negative controls[35].

Although there are several mechanisms proposed in H. pylori and insulin resistance association, there is not enough data to clarify the effects of H. pylori eradication on insulin resistance. Some studies showed the favorable effect of H. pylori eradication therapy on insulin resistance and metabolic syndrome components[11,17]. However, other studies do not support this benefit[12].

CONCLUSION

The most important, different and new data in this study is the documentation of benefit of H. pylori eradication in people with normal blood glucose concentrations. The results showed favorable changes in all indices of blood glucose metabolism such as, HbA1c, HOMA, insulin levels after H. pylori eradication. Then the question might arise: who will benefit? Will we give it to all the people with H. pylori? In this regard, BMI higher than 25 mg/m² could be helpful. Eradication in patients with BMI>25 mg/m² had effects both on insulin resistance and HbA1c. On the other hand, eradication yielded only HbA1c decrease in patients with BMI less than 25 mg/m². We propose H. pylori as a predisposing factor in diabetes development. However, further studies are necessary to establish this pathogenesis.

ACKNOWLEDGMENT

Author contributions: ZD, LF: study design; ZD: literature search; ZD, BE, MS: data collection and analysis; ZD, LF: data interpretation; LF: manuscript revision. Conflict of interest statement: None declared.

REFERENCES


